宜明昂科-B(01541.HK) 公布，获中国国家药监局批准进行“IMM0306”用于治疗狼疮性肾炎(LN)的II期临床试验。
据介绍，相关药物是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子，透过抑制CD47-SIRPα相互作用来阻断“别吃我”讯号，增强Fc-FcyRIIa和Fc-FcyRIIIa相互作用来激活巨噬细胞和NK细胞，并优先结合CD20而非CD47，以有效消除恶性B细胞，同时将毒性降至最低，从而可改善治疗效果。
另外，宜明昂科拥有“IMM0306”的全球知识产权及商业化权利。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2024-11-29 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.